Topics:
Sarcoma • Medical Oncology
Would you offer adjuvant avapritinib or imatinib for a high-risk, PDGFR D842V-mutated GIST after resection?
Data suggest patients with D842V-mutated or KIT/PDGFRA WT GIST do not respond to imatinib, but NCCN guidelines does not take into consideration mutational status for adjuvant therapy. With that, which high-risk GIST patients should NOT be offered adjuvant imatinib?
Answer from: Medical Oncologist at Academic Institution
In my opinion, there is no role for adjuvant imatinib in this population for a number of reasons. First of all, "WT" GIST usually has a very good prognosis. "The median disease-free survival in adults was 10 years while the 5-year overall survival was 88%." (Bhatt et al, 2016). Therefore, these pati...
Sign in or Register to read more